Key result
BIOMONITOR III insertion achieves 100% success with rapid placement and reliable home monitoring transmission.
Why the study?
BIOMONITOR III is a novel miniaturized implantable cardiac monitor with a long sensing vector, dedicated single-step insertion tool, and daily automatic Home Monitoring function needing clinical evaluation.
Does the BIOMONITOR III implantable cardiac monitor provide reliable sensing, good handling characteristics, and successful home monitoring in patients with ICM indications?
Observational (n=47)
Yes
Does the BIOMONITOR III implantable cardiac monitor provide reliable sensing, good handling characteristics, and successful home monitoring in patients with ICM indications?
The BIOMONITOR III implantable cardiac monitor demonstrates fast insertion, reliable R-wave sensing, good P-wave visibility, and highly successful home monitoring transmissions.
Early single-arm experience supports feasible BIOMONITOR III insertion with stable sensing; leaves open comparative performance versus other ICMs.
BACKGROUND: Implantable Cardiac Monitors (ICMs) are used for long-term monitoring of arrhythmias. BIOMONITOR III is a novel ICM with a miniaturized profile, long sensing vector due to a flexible antenna, simplified implantation with a dedicated insertion tool for pocket formation and ICM placement in a single step, and daily automatic Home Monitoring (HM) function. METHODS: In 47 patients undergoing BIOMONITOR III insertion for any ICM indication, 16 investigators at 10 Australian sites assessed handling characteristics of the insertion tool, R-wave amplitudes, noise burden, P-wave visibility, and HM transmission success. Patients were followed for 1 month. RESULTS: All 47 attempted insertions were successful. Median time from skin incision to removal of the insertion tool after ICM insertion was 39 s (IQR 19-65) and to wound closure and cleaning was 4.7 min (IQR 3.5-7.8). All aspects of the insertion tool were rated as "good" or "excellent" in ≥97.9% and "fair" in ≤2.1% of patients, except for "force needed for tunnelling" (91.5% good/excellent, 8.5% fair). Based on HM data, R-waves in the first month were stable at 0.70 ± 0.37 mV. Median noise burden (disabling automatic rhythm evaluation) was 0.19% (IQR 0.00-0.93), equivalent to 2.7 min (IQR 0.0-13.4) per day. In HM-transmitted ECG strips with regular sinus rhythm, P-waves were visible in 89 ± 24% of heart cycles. Patient-individual automatic Home Monitoring transmission success was 98.0% ± 5.5%. CONCLUSIONS: The novel ICM performed well in all aspects studied, including fast insertion, reliable R-wave sensing, good P-wave visibility, and highly successful HM transmissions.
No takes yet. Share an insight, caveat, or question.
Mariani et al. (2020) conducted an observational in Arrhythmias (any ICM indication) (n=47). BIOMONITOR III implantable cardiac monitor was evaluated on Insertion success, handling characteristics, R-wave amplitudes, noise burden, P-wave visibility, and Home Monitoring transmission success. Insertion of the BIOMONITOR III implantable cardiac monitor was successful in 100% of patients, with a median insertion time of 39 seconds and 98.0% home monitoring transmission success.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: